Show simple item record

dc.contributor.authorR. Gross, Ericen_US
dc.contributor.authorNithipatikom, Kasemen_US
dc.contributor.authorK. Hsu, Annaen_US
dc.contributor.authorN. Peart, Jasonen_US
dc.contributor.authorR. Falck, Johnen_US
dc.contributor.authorCampbell, William C.en_US
dc.contributor.authorJ. Gross, Garretten_US
dc.date.accessioned2017-05-03T13:03:44Z
dc.date.available2017-05-03T13:03:44Z
dc.date.issued2004en_US
dc.date.modified2009-09-28T06:51:19Z
dc.identifier.issn00222828en_US
dc.identifier.doi10.1016/j.yjmcc.2004.10.008en_AU
dc.identifier.urihttp://hdl.handle.net/10072/25830
dc.description.abstractInhibition of 20-hydroxyeicosatrienoic acid (20-HETE), by pretreatment with pharmacological inhibitors of cytochrome P450 (CYP) ?-hydroxylase, has been shown to reduce infarct size in canines when administered prior to ischemia. However, it is unknown whether these agents reduce infarct size when administered just prior to reperfusion and if the sarcolemmal and/or mitochondrial KATP channels (sKATP and mKATP) contribute to cardioprotection. Therefore, we determined whether specific CYP inhibitors for epoxygenases and ?-hydroxylases are cardioprotective when given either prior to ischemia or prior to reperfusion and furthermore, if selective inhibition of the sKATP by HMR-1098 or mKATP by 5-hydroxydecanoic acid (5-HD) could abrogate this effect. Male Sprague-Dawley rats underwent 30 minutes of ischemia followed by 2 hours of reperfusion. Groups received either miconazole (MIC, non-selective CYP inhibitor, 3 mg/kg), 17-octadecynoic acid (17-ODYA, CYP ?-hydroxylase inhibitor, 0,3 or 3 mg/kg), N-methylsulfonyl-12, 12-dibromododec-11-enamide (DDMS, CYP ?-hydroxylase inhibitor, 0,4 or 4 mg/kg), N-methanesulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH, CYP epoxygenase inhibitor, 3 mg/kg), or vehicle either 10 minutes prior to ischemia or 5 minutes prior to reperfusion. Rats also received either HMR-1098 (6 mg/kg) or 5-HD (10 mg/kg) 10 minutes prior to reperfusion, with subsets of rats also receiving either MIC or 17-ODYA 5 minutes prior to reperfusion. DDMS and 17-ODYA dose dependently reduced infarct size. Rats treated with MIC, 17-ODYA and DDMS, but not MS-PPOH, produced comparable reductions in infarct size when administered prior to ischemia or reperfusion compared to vehicle. HMR-1098, but not 5-HD, also blocked the infarct size reduction afforded by MIC and 17-ODYA. These data suggest a novel cardioprotective pathway involving CYP ?-hydroxylase inhibition and subsequent activation of the sKATP channel during reperfusion.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherAcademic Pressen_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofpagefrom1245en_US
dc.relation.ispartofpageto1249en_US
dc.relation.ispartofissue6en_US
dc.relation.ispartofjournalJournal of Molecular and Cellular Cardiologyen_US
dc.relation.ispartofvolume37en_US
dc.subject.fieldofresearchcode320503en_US
dc.titleCytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channelen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2004
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record